We are developing antisense RNA treatments
against genetic diseases.

Anti-microRNAs for the treatment of Myotonic Dystrophy

Our main objective is finding effective treatments to unmet medical needs. The first target of the company will be to investigate anti-microRNAs for the treatment of myotonic dystrophy Type 1 (DM1), which is an orphan disease affecting more than 900.000 people worldwide (estimated prevalence 1/8000). Our research has reveled new therapeutic targets to treat the disease. The target and the mechanism of action of our molecules is new, and no other competitor has developed a similar approach.

“antisense RNAs treatments for genetic disorders”.
Our crew

Meet our passionate team

Our Board of Advisor

Our Investors